By Sheeba M. | May 23, 2026
Cannabis Rescheduling: The $2B Opportunity for MSO Margins
The cannabis industry has long labored under Section 280E of the Internal Revenue Code—a provision that prevents businesses from deducting ordinary business expenses when trafficking Schedule I controlled substances. For multi-state operators (MSOs), this translates to an effective tax rate 30-40 percentage points higher than traditional retailers.
But momentum is building. Recent signals from the DEA and bipartisan Congressional interest suggest cannabis rescheduling could happen within 18-24 months. If Schedule III occurs, the math changes dramatically.
The 280E Tax Cliff
Today, Curaleaf reports adjusted EBITDA of ~$800M on revenue of $1.4B. But that’s after 280E taxation effectively reduces net margins to single digits. Post-rescheduling, standard business deductions would apply—meaning:
- COGS deductions: ~$400M annually
- Operating expense deductions: ~$300M annually
- Tax savings at 21% federal + state: ~$140-180M per annum
For Verano Holdings, with Q1 2026 margins already improving, rescheduling could accelerate FCF generation by 35-40%.
Smaller operators like Green Thumb Industries would see proportional relief, potentially re-rating on cash flow multiples comparable to traditional retail CPG.
Timeline and Catalysts
The HHS review (due mid-2026) will determine DEA scheduling recommendations. If positive, DEA action could follow by Q4 2026. Markets typically front-run policy—expect significant re-rating 6-12 months ahead of final ruling.
Sources
- IRS Publication 334 — Section 280E guidance
- Congressional Record — Recent cannabis policy discussions
- DEA — Rescheduling review status
Track Curaleaf, Verano, and Green Thumb with the Weedstock Real-Time Tracker.